ID   AN3-CA
AC   CVCL_0028
SY   AN3_CA; AN3 CA; AN3 Ca; AN3CA; AN-3; AN3; Acanthosis Nigricans 3rd attempt-CArcinoma
DR   BTO; BTO_0001771
DR   CLO; CLO_0001722
DR   CLO; CLO_0037160
DR   EFO; EFO_0002110
DR   ArrayExpress; E-MTAB-38
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-111
DR   BCRJ; 0363
DR   BioSample; SAMN03471092
DR   BioSample; SAMN03473131
DR   BioSample; SAMN03473336
DR   BioSample; SAMN10988375
DR   cancercelllines; CVCL_0028
DR   CCRID; 4201HUM-CCTCC00127
DR   CCTCC; GDC0127
DR   Cell_Model_Passport; SIDM00901
DR   ChEMBL-Cells; CHEMBL3308708
DR   ChEMBL-Targets; CHEMBL1075392
DR   CLS; 300119
DR   Cosmic; 687550
DR   Cosmic; 699283
DR   Cosmic; 713473
DR   Cosmic; 713495
DR   Cosmic; 809134
DR   Cosmic; 846176
DR   Cosmic; 871551
DR   Cosmic; 889116
DR   Cosmic; 910781
DR   Cosmic; 980634
DR   Cosmic; 1007162
DR   Cosmic; 1057760
DR   Cosmic; 1066221
DR   Cosmic; 1070810
DR   Cosmic; 1102376
DR   Cosmic; 1105620
DR   Cosmic; 1177683
DR   Cosmic; 1223484
DR   Cosmic; 1434192
DR   Cosmic; 1576450
DR   Cosmic; 1622894
DR   Cosmic; 1696752
DR   Cosmic; 2030460
DR   Cosmic; 2646618
DR   Cosmic-CLP; 910781
DR   DepMap; ACH-000940
DR   DSMZ; ACC-267
DR   DSMZCellDive; ACC-267
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 910781
DR   GEO; GSM374970
DR   GEO; GSM375429
DR   GEO; GSM827494
DR   GEO; GSM886869
DR   GEO; GSM887934
DR   GEO; GSM1669600
DR   GEO; GSM3161710
DR   GEO; GSM3161711
DR   GEO; GSM7701431
DR   GEO; GSM7701432
DR   IARC_TP53; 21175
DR   IGRhCellID; AN3CA
DR   IZSLER; BS TCL 200
DR   LiGeA; CCLE_574
DR   LINCS_LDP; LCL-1499
DR   PharmacoDB; AN3CA_63_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0028
DR   PubChem_Cell_line; CVCL_0028
DR   TOKU-E; 543
DR   Wikidata; Q54749896
RX   PubMed=327080;
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=11668190;
RX   PubMed=14207855;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20218740;
RX   PubMed=20944090;
RX   PubMed=22460905;
RX   PubMed=22710073;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   Info; HPA; -; https://www.proteinatlas.org/learn/cellines
WW   Info; MCLP; -; https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: ERK genetic alteration cell panel (ATCC TCP-1033).
CC   Part of: Human Protein Atlas, Cell Atlas panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: PTEN genetic alteration cell panel (ATCC TCP-1030).
CC   Population: Caucasian.
CC   Doubling time: ~45-50 hours (CLS=300119); ~55 hours (DSMZ=ACC-267).
CC   HLA typing: A*11:01,11:01; B*15:11,58:01; C*05:01,06:02 (PubMed=26589293).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; HGNC:6877; MAPK3; Simple; p.Pro373Ser (c.1117C>T); Zygosity=Heterozygous (ATCC=HTB-111).
CC   Sequence variation: Mutation; HGNC; HGNC:8979; PIK3R1; Simple; p.Arg557_Lys561delArgGluIleAspLysinsGln (c.1670_1681delGAGAAATTGACA); Zygosity=Heterozygous (ATCC=HTB-111).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Arg130Glnfs*4 (c.389delG); ClinVar=VCV000192224; Zygosity=Homozygous (PubMed=20944090; ATCC=HTB-111).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gly389Trp (c.1165G>T); ClinVar=VCV000156517; Zygosity=Heterozygous (ATCC=HTB-111).
CC   Omics: Genomics; Chromatin accessibility; ATAC-seq.
CC   Omics: Genomics; DNA methylation analysis.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Phenotyping; Drug screening.
CC   Omics: Proteomics; Expression; Large antibody panel staining analysis.
CC   Omics: Proteomics; Expression; Reverse-phase protein array.
CC   Omics: Proteomics; Quantitative.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; Array-based CGH.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0.36%; Native American=0%; East Asian, North=0.85%; East Asian, South=1.08%; South Asian=3.21%; European, North=62.96%; European, South=31.54% (PubMed=30894373).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): ATCC=HTB-111; CLS=300119; Cosmic-CLP=910781; DSMZ=ACC-267; IZSLER=BS TCL 200; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 12,14 (DSMZ=ACC-267)
ST   CSF1PO: 12,14,15 (ATCC=HTB-111; CLS=300119; Cosmic-CLP=910781; IZSLER=BS TCL 200; PubMed=25877200)
ST   D13S317: 12,14
ST   D16S539: 10,14 (ATCC=HTB-111; CLS=300119; DSMZ=ACC-267; PubMed=25877200)
ST   D16S539: 10,14,15 (Cosmic-CLP=910781; IZSLER=BS TCL 200)
ST   D18S51: 15,18
ST   D19S433: 14
ST   D21S11: 29,30
ST   D2S1338: 20,23
ST   D3S1358: 17
ST   D5S818: 11,14
ST   D7S820: 7,7.1,10 (ATCC=HTB-111; PubMed=25877200)
ST   D7S820: 7,10 (CLS=300119; Cosmic-CLP=910781; IZSLER=BS TCL 200)
ST   D7S820: 7.1,10 (DSMZ=ACC-267)
ST   D8S1179: 12,14
ST   FGA: 23
ST   Penta D: 9,11
ST   Penta E: 9,16
ST   TH01: 9.3,10
ST   TPOX: 8,10
ST   vWA: 14,20
DI   NCIt; C26687; Acanthosis nigricans
DI   NCIt; C40145; Type I endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   55Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 45
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=14207855; DOI=10.1093/jnci/33.3.441;
RA   Dawe C.J., Banfield W.G. 2nd, Morgan W.D., Slatick M.S.,
RA   Ollendorf-Curth H.;
RT   "Growth in continuous culture, and in hamsters, of cells from a
RT   neoplasm associated with acanthosis nigricans.";
RL   J. Natl. Cancer Inst. 33:441-456(1964).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20218740; DOI=10.1177/153303461000900207; PMCID=PMC5120669;
RA   Wang Y.-M., Yang D., Cogdell D., Hu L.-M., Xue F.-X., Broaddus R.,
RA   Zhang W.;
RT   "Genomic characterization of gene copy-number aberrations in
RT   endometrial carcinoma cell lines derived from endometrioid-type
RT   endometrial adenocarcinoma.";
RL   Technol. Cancer Res. Treat. 9:179-189(2010).
//
RX   PubMed=20944090; DOI=10.1126/scitranslmed.3001538;
RA   Dedes K.J., Wetterskog D., Mendes-Pereira A.M., Natrajan R.,
RA   Lambros M.B., Geyer F.C., Vatcheva R., Savage K., Mackay A.,
RA   Lord C.J., Ashworth A., Reis-Filho J.S.;
RT   "PTEN deficiency in endometrioid endometrial adenocarcinomas predicts
RT   sensitivity to PARP inhibitors.";
RL   Sci. Transl. Med. 2:53ra75.1-53ra75.8(2010).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017; PMCID=PMC3432677;
RA   Korch C.T., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K.,
RA   Lessey B.A., Jordan V.C., Bradford A.P.;
RT   "DNA profiling analysis of endometrial and ovarian cell lines reveals
RT   misidentification, redundancy and contamination.";
RL   Gynecol. Oncol. 127:241-248(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//